Clover Announces Positive Preliminary Phase I Results for Bivalent RSV Vaccine Candidate SCB-1019 in Initial Young Adult Cohort
-- Bivalent SCB-1019 significantly boosted RSV-A and RSV-B neutralization titers to approximately 6,600 IU/mL (6.4-fold increase) and approximately 46,000 IU/mL (12-fold increase), respectively -- -- Preliminary Phase I data in target older adult population is on track for H2-2024 -- SHANGHAI, ...
Clover Announces Positive Phase Ⅰ Results for SCB-219M for Treatment of Chemotherapy-Induced Thrombocytopenia (CIT)
--All CIT patients maintained platelet counts >75 x 109/L at 1-week following chemotherapy plus a single dose of SCB-219M, with durable responses through at least 3-weeks-- --Durable efficacy and PK profile expected to support convenient dosing interval of ≥2-weeks, compared to daily or weekly d...
Clover Initiates Phase Ⅰ Clinical Trial for RSV Vaccine Candidate
--First Chinese RSV PreF Vaccine Candidate to Enter Clinical Trial Stage--
SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
Clover Completes BLA Submission for Seasonal Influenza Vaccine in Brazil
-- Clover's seasonal influenza vaccine BLA submission has been completed in
Brazil, boosting Clover's global presence --
SHANGHAI, Nov. 7, 2023 /PRNewswire/ -- Clover Biopharmaceuticals, Ltd.
